ATNM vs RNW

For growth investors, ReNew Energy Global Plc (RNW) is the stronger pick with 19.

4% revenue growth year-over-year, versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). ReNew Energy Global Plc (RNW) offers the better valuation at 46. 9x trailing P/E (0. 4x forward), making it the more compelling value choice. Analysts rate ReNew Energy Global Plc (RNW) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ReNew Energy Global Plc (RNW) delivered a total return of -45.

7%, compared to -83. 3% for Actinium Pharmaceuticals, Inc. (ATNM). Over 10 years, the gap is even starker: RNW returned -50. 5% versus ATNM's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ReNew Energy Global Plc (RNW) is the lower-risk stock at 0.

62β versus Actinium Pharmaceuticals, Inc. 's 1. 40β — meaning ATNM is approximately 124% more volatile than RNW relative to the S&P 500. On balance sheet safety, Actinium Pharmaceuticals, Inc. (ATNM) carries a lower debt/equity ratio of 5% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ReNew Energy Global Plc (RNW) is pulling ahead at 19.

4% versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). On earnings-per-share growth, the picture is similar: Actinium Pharmaceuticals, Inc. grew EPS 30. 6% year-over-year, compared to 10. 1% for ReNew Energy Global Plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ReNew Energy Global Plc (RNW) is the more profitable company, earning 3.

9% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps 3. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ReNew Energy Global Plc (RNW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

62)). Both have compounded well over 10 years (RNW: -50. 5%, ATNM: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ATNM (Healthcare) and RNW (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ATNM is a small-cap quality compounder stock; RNW is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.